Regor Therapeutics has commenced a Phase II clinical trial for its oral glucagon-like peptide-1 (GLP-1) agonist, RGT-075, designed for adults with obesity or overweight with weight-linked comorbidities.
The announcement is in line with the trial’s ‘First Patient First Visit’ (FPFV) milestone.
Go deeper with GlobalData
This study aims to assess the tolerability, safety, pharmacokinetics, and pharmacodynamics of RGT-075 versus a placebo.
The randomised, multicentre, double-blind, placebo-controlled trial will involve nearly 60 adult subjects.
These individuals should have a body mass index (BMI) of ≥27kg/m² and ≤45kg/m² to be part of the trial. They will be randomised to receive either a once-a-day oral dose of RGT-075 or a placebo.
The 12-week treatment regimen will begin with a six-week titration period, followed by six weeks at the target dose.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRegor anticipates reporting topline data for this Phase II in the second half of this year.
A once-daily, orally available small molecule GLP-1 receptor (GLP1R) full agonist, RGT-075 was discovered and developed by Regor to treat metabolic ailments such as type-2 diabetes mellitus and obesity.
The company concluded Phase I single ascending dose (SAD) and multiple ascending dose (MAD) studies of RGT-075, where it demonstrated safety and was well-tolerated.
Established in 2018, Regor uses its Computer Accelerated Rational Discovery (rCARD) platform for drug development.
It has concluded eight proof of concept candidates (PCCs) in-house and submitted five investigational new drug (IND) applications expediting the discovery of novel therapeutic agents.
Regor’s pipeline includes products in metabolism, oncology, and auto-immunity.
In addition to RGT-075, the assets include RGT-419B, being developed to treat refractory estrogen receptor positive / human epidermal growth factor receptor 2 negative (ER+/HER2) breast cancer patients.
Regor Therapeutics metabolic diseases head Michael Grimm said: “The initiation of the Phase II trial marks an important milestone in the development of RGT-075 as we believe it could represent a convenient and potentially meaningful alternative to the currently available weight loss treatments.
“RGT-075 is designed to be administered orally once daily as a monotherapy or as part of a potential oral combination treatment for obesity. Phase I clinical data showed promising exploratory body weight trends despite short treatment duration.”
